JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
Product Usage: This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation is allowed to use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website for educational purpose only. Bodily introduction of any kind into humans and animals is strictly forbidden by law. This product should only be handled by licenced qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused as a drug, food and cosmetic.
FREE Shipping for orders over $200
For this product you will need: BACTERIOSTATIC WATER For reconstitution.
IGF-1 DES is an incomplete variant of insulin-like growth factor-1 (IGF-1 DES), a naturally occurring endocrine hormone produced in the body. It is a 67 amino acid peptide and thereby represents the latter half of the fully functional IGF-1 polypeptide which includes 70 amino acids. Such structural divergence changes receptor binding kinetics and affects interactions with IGF-binding proteins (IGFBPs), rendering an interesting molecular profile that can be used for in vitro and mechanistic studies.
IGF-1 DES activates IGF-1 receptors in various cellular tissues and can act as both a growth-induced signaling factor, as well as postdevelopment maintenance factor. These features make it an important molecular tool to probe receptor-ligand kinetics, downstream transcriptional actions and signal modulation under defined conditions of perturbation. IGF-1 DES is intended for research use only.
From Pubchem
Â
Synonyms: Insulin-like growth factor 1, des-(1-3)-, Des(1-3)igf-I Molecular Weight: 7365.4225 g/molMolecular Formula: C319H495N91O96S7 CAS Number: 112603-35-7 PubChem CID: 135331146
Preclinical studies have examined the effects of IGF-1 DES on myotrophic cellular phenotypes, including proliferation, differentiation, and myofibroblast lineage progression. Experimental evidence indicates that variations in IGF-1 DES promoters contribute to differences in musculoskeletal traits and muscle-specific gene expression. Mechanistic analysis highlights signaling through the PI3K/Akt pathway, with increased expression of cell cycle regulatory genes and myoblast proliferation, effects that are attenuated by selective PI3K and Akt inhibitors [1,2,3].
The N-terminal truncation of IGF-1 to generate IGF-1 DES reduces binding to IGF-binding proteins (IGFBPs), resulting in enhanced receptor activation and anabolic signaling compared to full-length IGF-1. This modification also enables rapid systemic clearance, producing a fast onset and short duration of effect. Comparative preclinical studies in marmoset and porcine models demonstrate 2–3-fold higher bioactivity for IGF-1 DES versus native IGF-1, supporting its use as a mechanistic probe in endocrine and metabolic signaling research [4,5,6].
IGF-1 DES has been investigated for its effects on neurotrophic pathways, including synaptic transmission, neuronal survival, and plasticity. Experimental models show potentiation of excitatory post-synaptic currents via AMPA receptor-dependent mechanisms involving the PI3K pathway. Long-term administration in preclinical models enhances neurogenesis, microvascular density, and regional cerebral glucose utilization, highlighting its application in studies of neuronal maintenance, cognitive function, and neurodevelopmental signaling [7,8,9].
IGF-1 DES has also been evaluated in bone tissue signaling, affecting both osteoblast and osteoclast pathways. Preclinical studies report stimulation of bone formation and resorption, indicating a role in bone homeostasis and remodeling. Additional research highlights its involvement in skeletal repair, maturation, and regenerative processes, underscoring its relevance in osteotropic mechanistic analyses [10,11].
IGF-1 DES participates in neurodevelopmental signaling, synapse formation, and apoptosis regulation. Biochemical studies indicate effects on microRNA (miR-339-5p) and p38 MAPK-associated pathways. Preclinical and translational research shows that IGF-1 DES influences synaptic connectivity and neural circuitry development, supporting its relevance in neurobiological and cognitive research [12,13,14].
IGF-1 DES is a truncated form of IGF-1 with enhanced receptor binding and activity in preclinical models. Its mechanisms span myogenesis, osteotropic signaling, and neurotrophic pathways, making it a versatile molecular tool for both in vitro and in vivo research. IGF-1 DES is supplied exclusively for research and educational purposes by Element CRP, with distribution limited to qualified and licensed investigators.
IGF-1 DES is a synthetic 67-amino-acid truncated analogue of IGF-1 lacking the first three N-terminal amino acids. The deletion confers reduced binding to IGF-binding proteins relative to native IGF-1 while preserving receptor engagement, supporting in vitro research applications focused on direct receptor pharmacology.
Cell-based research with IGF-1 DES investigates IGF-1 receptor engagement in cell models where IGFBP interference complicates interpretation, including myocyte cultures and various cancer cell lines. Standard functional readouts include receptor autophosphorylation, Akt and ERK pathway activation, and downstream protein synthesis markers.
Element CRP supplies this product at 1mg per vial. USA-manufactured via solid-phase peptide synthesis and verified at 99%+ purity by HPLC and Mass Spectrometry. Reconstitution with bacteriostatic water required. Store lyophilised at -20°C; stable for 24 months.
WARNING: For research use only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any disease. For use by qualified research professionals only.
Forgot password?
Country: United States (US-only registration)
All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.
Element CRP is a chemical supplier. Element CRP is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. Element CRP is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act.
